Celcuity LLC (CELC NASDAQ) stock market data APIs
$130.3714
0.36(0.3%)
as of May 8, 2026
Try our APIs with
free plan!
Celcuity LLC Financial Data Overview
Price chart is built with
Anychart
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Prev. Close
130.3714
Open
131.4686
High
133.0201
Low
128.3163
52 wk Range
9.51-151.02
Market Cap
6 335 M
Shares Outstanding
48 337 K
EPS
-0.73
Beta
0.093
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Celcuity LLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Celcuity LLC data using free add-ons & libraries
Get Celcuity LLC Fundamental Data
Celcuity LLC Fundamental data includes:
- Net Revenue:
- EBITDA: -172 024 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-19
- EPS/Forecast: -1.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Celcuity LLC News
New
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Key Points ACT Capital Management acquired 174,250 ALMS shares in the first quarter, with an estimated trade value of $4.36 million based on average first-quarter pricing. The quarter-end position va...
Stocks Fall Amid Rising Middle East Tensions
The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.41%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.21%. June E-...
Stocks Fall Amid Rising Middle East Tensions
The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.41%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.21%. June E-...
Top Midday Gainers
Celcuity (CELC) reported late Friday positive topline results from a cohort of its phase 3 Viktoria- PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get Celcuity LLC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
